---
title: "IGF-1 (overview)"
canonical_url: https://peptidelibrary.app/library/igf-1
description: "Endogenous growth factor. Recombinant mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency. Research vials are unapproved. WADA S2."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# IGF-1 (overview)

IGF-1 (overview), also called Mecasermin or Increlex, is a research peptide in the IGF-1 receptor agonist class. Insulin-like growth factor 1 is a 70-amino-acid peptide produced mainly by the liver under growth hormone stimulation, and it mediates most of the anabolic effects attributed to growth hormone.

Endogenous growth factor. Recombinant mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency. Research vials are unapproved. WADA S2.

Also known as: Mecasermin, Increlex, Somatomedin-C, IGF-I.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: IGF-1 / prescription (mecasermin)
- Mechanism class: IGF-1 receptor agonist
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Insulin-like growth factor 1 is a 70-amino-acid peptide produced mainly by the liver under growth hormone stimulation, and it mediates most of the anabolic effects attributed to growth hormone. It activates the IGF-1 receptor, a tyrosine kinase that signals through PI3K/Akt and MAPK to promote protein synthesis, cell proliferation and survival. In circulation over ninety percent is bound to IGF binding proteins, principally IGFBP-3 with the acid-labile subunit, which buffers free concentrations and extends half-life from minutes to hours. At high concentrations it cross-reacts with the insulin receptor, which is why hypoglycaemia is the characteristic acute risk of excess free IGF-1.

Targets: IGF-1 receptor.

Origin: Endogenous 70-aa peptide; recombinant pharmaceutical form exists.

## Properties

- Molecular weight: 7,649 g/mol
- CAS number: 67763-96-6
- Half-life: ~10–16 hours (bound); minutes unbound
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. INCRELEX (mecasermin) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Paediatric patients aged 2+ with severe primary IGF-1 deficiency, or GH gene deletion with neutralising antibodies to GH. Treatment of growth failure [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b27a1b-a611-4f91-ad22-76d4b390c3ae)
2. INCRELEX (mecasermin) injection — FDA prescribing information (Eton Pharmaceuticals), DailyMed. Regulatory label (FDA), human. Population: Same approved population as the reference product. Treatment of growth failure [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5b2b0e1-c523-468d-9a0b-4ae4e4a8dbce)

## Safety

Side effects: Hypoglycemia; Tonsillar hypertrophy; Intracranial hypertension.

Risks: WADA S2; Unapproved research IGF is not Increlex.

Human safety basis: FDA prescribing information

Key limitations: Not approved by the FDA for any use..

## Regulatory status

IGF-1 (overview) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is IGF-1 (overview)?

Endogenous growth factor. Recombinant mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency. Research vials are unapproved. WADA S2.

### How does IGF-1 (overview) work?

Insulin-like growth factor 1 is a 70-amino-acid peptide produced mainly by the liver under growth hormone stimulation, and it mediates most of the anabolic effects attributed to growth hormone. It activates the IGF-1 receptor, a tyrosine kinase that signals through PI3K/Akt and MAPK to promote protein synthesis, cell proliferation and survival.

### Is IGF-1 (overview) FDA approved?

No. IGF-1 (overview) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of IGF-1 (overview)?

Reported half-life for IGF-1 (overview) is ~10–16 hours (bound); minutes unbound. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is IGF-1 (overview) banned in sport?

IGF-1 (overview) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to IGF-1 (overview)?

Compounds most often compared with IGF-1 (overview) include Mecasermin, IGF-1 LR3, IGF-1 DES and MGF. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [FDA label — Increlex](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021839s021lbl.pdf)
- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Acromegaly: pathogenesis, diagnosis, and management — Lancet Diabetes Endocrinol, 2022](https://pubmed.ncbi.nlm.nih.gov/36209758/)
- [Doping and sports endocrinology: growth hormone, IGF-1, insulin, and erythropoietin — Rev Clin Esp (Barc), 2023](https://pubmed.ncbi.nlm.nih.gov/36736729/)
- [Insulin-Like Growth Factor 1 (IGF-1) Signaling in Glucose Metabolism in Colorectal Cancer — Int J Mol Sci, 2021](https://pubmed.ncbi.nlm.nih.gov/34208601/)
